stockrowEnliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) EPS (diluted)
Enliven Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$1.83, compared with −$1.89 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.67. Over the past ten years it has ranged from −$133.61 (fiscal 2019) to −$1.83 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Enliven Therapeutics, Inc. ranks 290th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.83 | — |
| FY2024 | −$1.89 | — |
| FY2023 | −$2.01 | — |
| FY2022 | −$12.05 | — |
| FY2021 | −$9.48 | — |
| FY2020 | −$14.12 | — |
| FY2019 | −$133.61 | — |
| FY2018 | −$2.62 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.49 | — |
| Mar 2026 | −$0.38 | — |
| Dec 2025 | −$0.48 | — |
| Sep 2025 | −$0.32 | — |
| 26 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| ELVN Enliven Therapeutics, Inc. | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item